Overview

Single Dosing Clinical Trial of HL151

Status:
Completed
Trial end date:
2016-02-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the pharmacokinetic characteristics of bepotastine after single oral administration of TALION tab, a IR formulation of bepotastine as reference drug and HL151, a SR formulation of bepotastine as test drug in healthy male adults. Additionally the safety and tolerability of two drugs will be evaluated.
Phase:
Phase 1
Details
Lead Sponsor:
Hanlim Pharm. Co., Ltd.